Seonix Bio Introduces SightScore: The First Clinical Polygenic Risk Score Test for Glaucoma in the US
Seonix Bio has launched SightScore in the United States, marking the first commercially available clinical polygenic risk score test for primary open-angle glaucoma (POAG). Previously introduced in Australia and New Zealand, SightScore is designed to facilitate early glaucoma detection and personalized treatment through a simple saliva-based genetic test.
How SightScore Works
SightScore analyzes millions of genetic variants in a patient’s genome to generate a personalized polygenic risk score. This score estimates an individual's genetic susceptibility to developing glaucoma or, in already diagnosed patients, evaluates the likelihood of disease progression.
By providing precise genetic risk assessments, SightScore enables clinicians to prioritize high-risk patients and tailor treatment approaches accordingly.
Expert Endorsements and Clinical Impact
“SightScore is a game changer in the way we assess and manage patients at risk for glaucoma. It is an invaluable tool for identifying individuals who may not show obvious signs of the disease yet and are at higher genetic risk,” said Inder Paul Singh, MD, President of The Eye Centers of Racine & Kenosha, Wisconsin.
Dr. Singh emphasized that integrating SightScore into clinical practice allows for earlier screening, personalized care plans, and improved disease management, ensuring glaucoma is detected at its most treatable stages.
A New Era in Genetic Risk Assessment for Glaucoma
Traditional genetic assessments for glaucoma have focused on single genes or a limited number of genetic variants. In contrast, SightScore analyzes 7 million genetic variants, making it the first true polygenic clinical risk score for glaucoma.
"In the past, clinical genetic risk assessment for glaucoma has targeted a single gene or tens of genetic variants. As the first truly polygenic clinical genetic risk score for glaucoma on the market, using 7 million genetic variants, SightScore represents a major step forward in how we diagnose and manage this disease," said Nick Haan, CEO of Seonix Bio.
